FNY Investment Advisers’s Iovance Biotherapeutics IOVA Stock Holding History

FNY Investment Advisers’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$24K	Sell	6,000 -2,000	-25%	-$7.6K	0.01%	506
2026 Q1	$28K	Sell	8,000 -10	-0.1%	-$32	0.01%	430
2025 Q4	$21K	Sell	8,010 -742	-8%	-$1.72K	0.01%	557
2025 Q3	$18K	Buy	8,752 +4,382	+100%	+$10.3K	0.01%	702
2025 Q2	$7K	Sell	4,370 -7,630	-64%	-$19K	﹤0.01%	703
2025 Q1	$39K	Buy	+12,000	New	+$61.9K	0.02%	319
2022 Q1	–	Sell	-1,300	Closed	-$20.1K	–	822
2021 Q4	$24K	Buy	+1,300	New	+$28.6K	0.01%	323
2020 Q4	–	Sell	-32,500	Closed	-$1.07M	–	855
2020 Q3	$1.07M	Buy	+32,500	New	+$996K	0.45%	60

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

FNY Investment Advisers's IOVA Position: Q2 2026 in Review

FNY Investment Advisers reduced its Iovance Biotherapeutics (IOVA) stake by 25% in Q2 2026, selling an estimated $7.6K and leaving 6,000 shares worth $24K. The position accounts for 0.01% of the portfolio, ranked #506.

FNY Investment Advisers first reported a position in IOVA in Q3 2020 and has held it in 8 quarters since. The position peaked at $1.07M in Q3 2020. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

FNY Investment Advisers held 6,000 shares of Iovance Biotherapeutics worth $24K as of Q2 2026.
FNY Investment Advisers sold 2,000 Iovance Biotherapeutics shares in Q2 2026, an estimated $7.6K.
Iovance Biotherapeutics made up 0.01% of FNY Investment Advisers's portfolio in Q2 2026, its #506 holding.
FNY Investment Advisers first reported a position in Iovance Biotherapeutics in Q3 2020 and has held it in 8 quarters since.
FNY Investment Advisers's Iovance Biotherapeutics position peaked at $1.07M in Q3 2020.
292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on FNY Investment Advisers's 13F filing for Q2 2026, filed 8 Jul 2026.